Invion Ltd
ASX:IVX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Invion Ltd
ASX:IVX
|
7.1m AUD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
985.1B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
554.2B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.8B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
224.3B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
281.3B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
150.9B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Invion Ltd
Glance View
Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatments for market opportunities in a variety of cancer indications, chronic inflammatory, and autoimmune diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-02-15. The firm is focused on the development of Photosoft technology for the treatment of a range of cancers. The firm is conducting various clinical trials for the development of its Photosoft technology. Its Photo Dynamic Therapy (PDT) is a treatment that optimizes the use of non-toxic photosensitizers and visible light to kill cancer and stimulate the immune system. The firm aims to develop photosensitizer, IVX-PDT, that improves the treatment of skin cancers and hard-to-treat solid cancers, such as those present in ovarian, prostate and lungs. Epitech Dermal Science Pty Ltd is the wholly owned subsidiary of the Company.
